Skip to main content
Clinical Trials/NCT02023138
NCT02023138UnknownNot Applicable

Evaluation of the Acceptability, Feasibility and Effectiveness of Two Methods of Involvement of Patients With Cognitive Disability in Clinical Guidelines Development: a Randomized Crossover Pilot Trial

Laval University1 site in 1 country20 target enrollmentStarted: January 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
20
Locations
1
Primary Endpoint
Acceptability

Study Overview

Brief Summary

There is a lack of evidence about the best method to involve the patient and population (IPP) into clinical practice guidelines (CPG) development. The goal of this pilot study is to document the acceptability, feasibility and effectiveness of two methods for the implication of patients with a traumatic brain injury (TBI) in CPG development. Method: A single blind, randomized crossover trial will be performed with patients having a TBI. Participants: A convenience sample of 20 patients a) with a moderate-to-severe TBI (Glascow Coma Scale <13), b) living with a TBI for two to four years, c) French-speaking, d) able to use a computer and e) able to participate in a two-hour group meeting will be recruited among the members of the Associations TCC Des Deux Rives. Procedures: The patients will first receive a in-person training on guidelines and IPP. They will be randomized into Group 1 or Group 2 by a researcher blinded to experimentation. They will experiment either group discussion (control intervention) or a Wiki (experimental intervention). Phase 1: A week after the training, Group 1 participants will be invited to a discussion group animated by an experimented moderator, where they will be asked to discuss a CPG recommendation chosen by the research team in an existing CPG. The participants will be asked : 1) about their opinion of the recommendation; 2) if they have a preference in regard to the recommendation ; 3) if they have some modification, correction or addition to bring to this recommendation. In the mean time, Group 2 participants will receive an email presenting a link to a Wiki. They will be invited to answer the same three questions as Group 1, but using a Wiki platform. The patients will have a week to interact and answer the questions; recalls could be sent by email if required. At the end of Phase 1, participants of both groups will fill a questionnaire documenting the acceptability of the method experimented. Phase 2: As per the crossover design, the Group 1 participants will then be assigned to the Wiki intervention and the Group 2 participants will be assigned to the discussion group intervention. The procedure will be repeated with a second recommendation. At the end of Phase 2, the patients will be asked to answer a short survey to validate their preferences about the two methods. Tools: The acceptability of the methods will be evaluated with a questionnaire adapted from Sidani and al. and validated with three TBI individuals. The feasibility of the intervention will be evaluated using a) the number of participants who reached the group or the Wiki, b) the number of participants who completed the intervention c) the number of support interventions required in the group and in the Wiki. The effectiveness of the two methods will be evaluated by submitting the adapted recommendations to a panel of expert clinicians evaluators blinded to the methodologies of recommendations adaptation. They will be invited to rate the clarity, accuracy, appropriateness and usefulness of the recommendations. Analysis: Feasibility indicators will be reported using descriptive statistics. Within-subject analysis using non-parametric statistics will be performed to assess the acceptability of the two methods. AC1 coefficient of raters' agreement will be calculated on the expert evaluation scores, and the effectiveness of the methods will be compared using appropriate non parametric statistics to. Impact: This pilot trial will be the first one to evaluate methodologies for involving disabled individuals into CPG development.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Health Services Research
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •having suffered a moderate-to-severe TBI (Glascow Coma Scale <13)
  • •living with a TBI for two to four years
  • •French-speaking
  • •able to use a computer
  • •able to participate in a two-hour group meeting

Exclusion Criteria

  • Not provided

Arms & Interventions

Focus group

Active Comparator

Intervention: Focus group (Other)

Focus group

Active Comparator

Intervention: Wiki (Other)

Wiki

Experimental

Intervention: Focus group (Other)

Wiki

Experimental

Intervention: Wiki (Other)

Outcomes

Primary Outcomes

Acceptability

Time Frame: Immediatly (less than 12 hours) after the intervention, at the end of week 2 and week 3.

The acceptability of the method will be evaluated through individual questionnaire administred seven days after having make the wiki available, or immediatly after the focus group.

Feasibility

Time Frame: At the end of the experimentation of the two methods (end of week 3)

The feasability will be assed by considering the number of participants reaching and using each method, and by recording the number of support intervention required for the use of each method.

Effectiveness

Time Frame: Within one month after the experimentation of the two methods.

After the adaptation of the two recommendations using the two methods, twenty experts, blind to the method used to formulate the recommendations, will rate each recommendation for its clarity, accuracy, appropriateness and usefulness of the recommendations using 10 points likert scales. An electronic questionnaire will be send to the experts and they will have one week to rate the recommendations.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Marie-Eve Lamontagne

Assistant professor

Laval University

Study Sites (1)

Loading locations...

Similar Trials